NANOSONICS LIMITED — Director's Dealing 2021

Sep 13, 2021

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Nanosonics Limited ABN 11 095 076 896

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Michael Kavanagh
Date of last notice	28 May 2021

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	a) Indirect Interest b) Indirect Interest c) Indirect Interest d) Indirect Interest e) Indirect Interest f) Direct Interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	a) Performance Rights held in the Nanosonics Omnibus Equity Plan b) Share Appreciation Rights held in the Nanosonics Omnibus Equity Plan c) Options held in the Nanosonics Omnibus Equity Plan e) Restricted shares held by the trustee of the Nanosonics Employee Equity Trust
Date of change	14 September 2021

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of securities held prior to change	a) 196,220 Performance Rights held in the Nanosonics Omnibus Equity Plan. b) 208,884 Share Appreciation Rights held in the Nanosonics Omnibus Equity Plan. c) 964,703 Options held in the Nanosonics Omnibus Equity Plan. d) 19,547 (Indirect) Ordinary Shares (restricted) e) 342,735 (Indirect) Ordinary Shares f) 1,018,363 (Direct) Ordinary Shares.
Class	a) Performance Rights b) Share Appreciation Rights c) Options d) Ordinary Shares e) Ordinary Shares f) Ordinary Shares
Number acquired	19,112 Ordinary Shares
Number disposed	19,112 Performance Rights held in the Nanosonics Omnibus Equity Plan
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	N/A
No. of securities held after change	a) 177,108 Performance Rights held in the Nanosonics Omnibus Equity Plan. b) 208,884 Share Appreciation Rights held in the Nanosonics Omnibus Equity Plan. c) 964,703 Options held in the Nanosonics Omnibus Equity Plan. d) 19,112 (Indirect) Ordinary Shares (restricted) e) 362,282 (Indirect) Ordinary Shares f) 1,018,363 (Direct) Ordinary Shares.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back	• Exercise of vested Performance Rights to ordinary shares subject to trading restriction under the terms and conditions of the Nanosonics Omnibus Equity Plan • End of trading restriction for shares issued under the terms and conditions of the Nanosonics Omnibus Equity

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to proceed during this period? If prior written clearance was provided, on what date was this provided?

Director: Mr. Michael Kavanagh Date: 14 September 2021

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3